




RealRate

PHARMACEUTICAL 2023

Immunome Inc.
Rank 340 of 446





PHARMACEUTICAL 2023

Immunome Inc.
Rank 340 of 446

The relative strengths and weaknesses of Immunome Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Immunome Inc. is the variable Net Income, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 96% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	22,649
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,331
Liabilities, Non-Current	62
Other Assets	716
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	5.0
Other Revenues	0
Property and Equipment	681
Research and Development	23,272
Selling, General and Administrative Expense	13,629

Output Variable	Value in 1000 USD
Assets	24,046
Liabilities	7,393
Expenses	36,901
Revenues	0
Stockholders Equity	16,653
Net Income	-36,896
Comprehensive Net Income	-36,896
Economic Capital Ratio	-53%